Article
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2013
Gautschi Oliver, Peters Solange, Zoete Vincent, Aebersold-Keller Franziska, Strobel Klaus, Schwizer Bernhard, Hirschmann Astrid, Michielin Olivier, Diebold Joachim
Abstract excerpt
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. We calculated a structure model of this very rare type of mutated BRAF kinase to explain the molecular mechanism of drug...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.